West Nile Virus Antibody Prevalence in Horses of Ukraine

Ute Ziegler 1, Artem Skrypnyk 2, Markus Keller 1, Christoph Staubach 3, Maksym Bezymennyi 2, Armando M. Damiani 4, Nikolaus Osterrieder 4 and Martin H. Groschup 1,*

1 Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Institute of Novel and Emerging Infectious Diseases, Südufer 10, D-17493 Greifswald-Insel Riems, Germany; E-Mails: ute.ziegler@fli.bund.de (U.Z.); markus.keller@fli.bund.de (M.K.); martin.groschup@fli.bund.de (M.H.G.)
2 Institute of Veterinary Medicine, National Academy of Agrarian Sciences of Ukraine, Donetska Str. 30, Kyiv, 03151, Ukraine; E-Mails: artemskrypnyk@yahoo.com (A.S.); nomax@ukr.net (M.B.)
3 Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Institute of Epidemiology, Seestraße 55, D-16868 Wusterhausen, Germany; E-Mail: christoph.staubach@fli.bund.de (C.S.)
4 Institut für Virologie, Zentrum für Infektionsmedizin, Freie Universität Berlin, Philippstr. 13, D-14163 Berlin, Germany; E-Mails: adamiani@zedat.fu-berlin.de (A.M.D.); no.34@fu-berlin.de (N.O.)

* Author to whom correspondence should be addressed; E-Mail: martin.groschup@fli.bund.de (M.H.G.); Tel.: +0049-38351-71163; Fax: +0049-38351-71191.

Received: 23 August 2013; in revised form: 30 September 2013 / Accepted: 1 October 2013 / Published: 4 October 2013

Abstract: West Nile virus (WNV) is a mosquito-borne virus of global importance. Over the last two decades, it has been responsible for significant numbers of cases of illness in humans and animals in many parts of the world. In Ukraine, WNV infections in humans and birds were first reported more than 25 years ago, yet the current epidemiological status is quite unclear. In this study, serum samples from over 300 equines were collected and screened in order to detect current WNV activity in Ukraine with the goal to estimate the risk of infection for humans and horses. Sera were tested by enzyme-linked immunosorbent assay (ELISA) and virus neutralization assay (NT) to detect WNV-specific antibodies. The results clearly revealed that WNV circulates in most of the regions from which samples were obtained, shown by a WNV seroprevalence rate of 13.5% of examined horses. This is the first topical report indicating the presence of WNV infections in horses.
in Ukraine, and the results of this study provide evidence of a widespread WNV circulation in this country.

**Keywords**: West Nile virus; neutralization; ELISA; serology; horse; Ukraine, prevalence, flavivirus

### 1. Introduction

West Nile virus (WNV) is an arbovirus that is maintained in an enzootic cycle between ornithophilic mosquitoes and certain wild bird species. WNV is the most widespread flavivirus known, was first isolated in Uganda in 1937, and has been found on all continents [1, 2], except for Antarctica. Distinct wild bird species serve as major reservoir hosts, although even under natural conditions a variety of mammalian and reptilian species are susceptible [3]. Likewise, a variety of different bird and mosquito species are involved in the WNV life cycle in various regions of the world [4]. WNV infections in humans and equines can lead to febrile illness, which in some cases will progress to encephalitis, occasionally with fatal outcome [5]. Outside of the African continent, WNV usually causes clinical cases only sporadically in humans and equines in Mediterranean countries, the Middle East, Romania and Russia [1, 6-8]. WNV encephalitis cases were first reported in humans and horses in the Camargue region of France in the early 1960s [9] and WNV has since been observed repeatedly in the central part of Europe [10]. Until the mid 1990s, WNV was considered a minor risk for humans and horses as — with some regional exceptions — it occurred only sporadically [11]. The first major WNV epidemic in Eastern Europe was observed in Romania in 14 districts of the lower Danube valley and in Bucharest with more than 400 clinical cases in 1996 [6]. In the late 1990s, outbreaks of WNV fever with high numbers of infected humans were also observed in Israel and southern Russia [12]. WNV infections became a major concern for veterinary public health after its introduction into the New World and rapidly spread to almost all countries on the American continent over the following years [13]. Large WNV outbreaks affecting humans and equines have been reported most recently in Greece [14], and WNV lineage 2 sequences could be demonstrated in human blood donors, *Culex* mosquitoes, wild birds and sentinel chickens. In the summer of 2012, evidence of WNV circulation was also found in Slovakia [15] and in various Balkan countries, including Serbia, Kosovo, Macedonia and Croatia [16]. Major outbreaks in humans and horses have also been observed over the past few years in the Mediterranean area, e.g. in Italy; however, preferentially WNV lineage 1 sequences have been detected [17]. Recently, WNV lineage 2 viruses have also been detected in wild birds in Sardinia [18] and in northeastern Italy.

In Ukraine, the earliest reports confirming the presence of WNV infections in humans and birds date back to the 1970s. In 1974, Sidenko *et al.* [19] described human WNV infections and the accompanying neurological signs, as well as WNV specific antibodies in wild birds and farm animals in the southwestern USSR. In 1985, 38 human cases, 16 of them with neurological manifestations, were recorded in the Transcarpathian region (Ukrainian SSR). The course of disease was benign [20]. At the same time (1980s), a WNV strain was detected in the blood and internal organs of a wild bird (Rook, *Corvus frugileus*) in the territory of the Black Sea [21]. A recently conducted study on
arbovirus infections showed new active natural foci in the forest-steppe zone of Ukraine and a close etiological relation was found between acute seasonal febrile diseases and the above-mentioned arbovirus. Besides tick-borne encephalitis, WNV disease, therefore, is the leading arboviral infection in the forest-steppe zone of Ukraine [22].

Recently, clinical WNV infections have been detected in patients in Ukraine in the summer of 2011 (eight WNV cases in three different regions/oblasts) and in 2012 (12 human cases in one region (Poltavska)) [23-25]. However, little is known about the extent of WNV infections in horses in Ukraine at present. The aim of the monitoring study (two-year-analysis) presented here was to investigate the prevalence of WNV specific antibodies in horse sera from 14 different Ukrainian regions (oblasts) by means of enzyme-linked immunosorbent assay (ELISA) and virus neutralization assays (NT). The results provide relevant information on the current WNV situation in Ukraine, involving an infection risk for humans and horses.

2. Results and Discussion

Horse sera from 310 animals kept in 14 different Ukrainian regions were collected in 2010 and 2011 (Figure 1, Table 1). Sera were screened by a commercial WNV competition ELISA, which essentially detects flavivirus antibodies. Therefore ELISA-positive results were verified by virus neutralization tests (NT) to identify WNV or cross-reactivity specific reactions.

Figure 1. Sampling sites of the horse sera with focus on known WNV risk areas.
Table 1. Distribution of serum samples by regions (oblasts).

| Ukraine region | investigated sera | by WNV-ELISA | only WNV-NT |
|----------------|-------------------|--------------|-------------|
| 1 Donetska     | 11                | 11           | -           |
| 2 Kharkivska   | 21                | 21           | -           |
| 3 Khmelnytska  | 39                | 38           | 1           |
| 4 Kyivska      | 118               | 113          | 5           |
| 5 Kirovohradska| 59                | 52           | 7           |
| 6 Luhanska     | 20                | 20           | -           |
| 7 Odeska       | 1                 | 1            | -           |
| 8 Poltavska    | 6                 | 6            | -           |
| 9 Rivnenska    | 13                | 11           | 2           |
| 10 Sumskan      | 2                 | 2            | -           |
| 11 Vinnytska   | 2                 | 2            | -           |
| 12 Volynska    | 10                | 10           | -           |
| 13 Zaporizka   | 6                 | 6            | -           |
| 14 Zhytomyrska | 2                 | 2            | -           |

Total 310 295 15

2.1. WNV competition Enzyme-linked immunosorbent assay (ELISA).

From the 310 sera, 295 samples were investigated using the competitive WNV ELISA. Volumes of the remaining 15 samples were so low (<50 µl) that they were only used for different NT (Table 1). The ELISA results showed a high rate of seropositive horses in different regions of Ukraine (Table 2). A total of 49 out of the 295 sera were reactive (Figure 2). Resulting in an overall ELISA prevalence rate of 16.6%, WNV antibody-positive animals were discovered in seven of the 14 investigated Ukrainian regions and high ELISA prevalence rates between 20% and 25% were determined for the Luhanska, Kharkivska and Kirovohradska regions. Even higher prevalence rates were obtained for Poltavska (33%) and Zaporizka (83%), with the caveat, however, that available sample numbers were small (n=6) (Table 2). All 49 ELISA-positive samples were investigated further by the different NT to exactly determine the virus resulting in ELISA seropositivity.

Table 2. Competitive ELISA results stratified by region and regional antibody prevalence.

| Ukraine region | comp. ELISA by ELISA | comp. ELISA negative | comp. ELISA reactive (doubtful or positive) | ELISA prevalence |
|----------------|-----------------------|-----------------------|--------------------------------------------|------------------|
| 1 Donetska     | 11                    | 11                    | -                                          | -                |
|   | Region       | Reactive | Negative | Indeterminate | Percentage |
|---|--------------|----------|----------|---------------|------------|
| 2 | Kharkivska   | 21       | 16       | 5             | 23.80 %    |
| 3 | Khmelnytska  | 38       | 37       | 1             | 2.63 %     |
| 4 | Kyivska      | 113      | 94       | 19            | 16.81 %    |
| 5 | Kirovohradska| 52       | 39       | 13            | 25.00 %    |
| 6 | Luhanska     | 20       | 16       | 4             | 20.00 %    |
| 7 | Odeska       | 1        | 1        | -             | -          |
| 8 | Poltavska    | 6        | 4        | 2             | 33.33 %    |
| 9 | Rivnenska    | 11       | 11       | -             | -          |
|10 | Sumska       | 2        | 2        | -             | -          |
|11 | Vinnytska    | 2        | 2        | -             | -          |
|12 | Volynska     | 10       | 10       | -             | -          |
|13 | Zaporizka    | 6        | 1        | 5             | 83.33 %    |
|14 | Zhytomyrska  | 2        | 2        | -             | -          |
|   | **Total**    | **295**  | **246**  | **49**        | **16.61 %**|

**Figure 2.** Competitive ELISA (S/N%) results of all 295 investigated horse sera. (1 = reactive samples, 2 = negative samples)
2.2. Virus neutralization assays (NT)

ELISA results were generally confirmed by NT results. In total, 68 horse sera (49 initially ELISA positive sera plus the 15 sera of which only small volumes were available and four additional sera, randomly selected) were investigated in a WNV neutralization assay. The ELISA results were confirmed for 42 out of the 49 ELISA-positive sera by WNV-NT, with neutralization titers ranging between 1:10 and 1:640 (Table 3). From the 15 sera with small volumes for which no ELISA results were available, three sera contained WNV-specific antibodies. One sample was excluded due to serum toxicity for cells.

Another seven sera with positive ELISA and negative WNV-NT results, as well as all sera with weak positive and positive WNV-NT results, were eventually run in a tick-borne encephalitis virus neutralization test (TBEV-NT) to check for cross-reactivity. False positive ELISA results caused by TBE cross-reactive antibodies had been observed in earlier serological studies looking at horses from Germany and Austria [26-28] which impede the interpretation of the ELISA results. However, no TBEV-NT positive horse serum was found among the Ukrainian horse sera (Table 3). Although Lozyn's'kyi and Vynohrad (1998 [22]) described the occurrence and wide distribution of tick-borne encephalitis in the forest-steppe zone of Ukraine, our sample panel revealed no incidence of a TBEV infection.

2.3. Indirect WNV IgM ELISA

ELISA-positive sera with clear NT negative or weak positive NT results, as well as sera, of which only small sample volumes (< 50µl) were available, were also run in a commercially available IgM ELISA to detect recent WNV infections. This capture ELISA detects WNV specific IgM antibodies in horse sera for up to 3 months post infection. However, none of the 23 investigated samples contained WNV IgM antibodies (data not shown). Therefore there was no evidence for recent WNV infections in these samples.

| Laboratory sample no. | comp. WNV-ELISA S/N% | WNV-ELISA results | NT-ND<sub>50</sub> (WNV lineage 2) | WNV-NT results | NT-ND<sub>50</sub> (TBEV-Neudoerfl) | TBEV-NT results |
|-----------------------|-----------------------|-------------------|-----------------------------------|-----------------|-----------------------------------|-----------------|
| ELISA and WNV-NT positive (n=42) | | | | | | |
| 33                    | 14.19%                | positive          | 10                                | weak positive   | < 10                               | negative        |
| 44                    | 12.28%                | positive          | 15                                | weak positive   | < 10                               | negative        |
| 53                    | 6.18%                 | positive          | 60                                | positive        | < 10                               | negative        |
| 54                    | 4.98%                 | positive          | 480                               | positive        | < 10                               | negative        |
| 58                    | 6.35%                 | positive          | 640                               | positive        | < 10                               | negative        |
| 59                    | 5.09%                 | positive          | 320                               | positive        | < 10                               | negative        |
| No. | Protein | Percentage | Status | No. | Protein | Percentage | Status |
|-----|---------|------------|--------|-----|---------|------------|--------|
| 64  |         | 4.73%      | positive | 640 |         | positive   | < 10   |
| 68  |         | 4.94%      | positive | 160 |         | positive   | < 10   |
| 69  |         | 4.87%      | positive | 640 |         | positive   | < 10   |
| 71  |         | 4.98%      | positive | 240 |         | positive   | < 10   |
| 72  |         | 4.83%      | positive | 160 |         | positive   | < 10   |
| 75  |         | 5.90%      | positive | 30  |         | positive   | < 10   |
| 88  |         | 5.53%      | positive | 40  |         | positive   | < 10   |
| 96  |         | 5.97%      | positive | 40  |         | positive   | < 10   |
| 97  |         | 4.91%      | positive | 160 |         | positive   | < 10   |
| 105 |         | 5.77%      | positive | 60  |         | positive   | < 10   |
| 107 |         | 4.73%      | positive | 160 |         | positive   | < 10   |
| 108 |         | 4.67%      | positive | 160 |         | positive   | < 10   |
| 123 |         | 7.86%      | positive | 80  |         | positive   | < 10   |
| 124 |         | 4.81%      | positive | 80  |         | positive   | < 10   |
| 128 |         | 4.15%      | positive | 160 |         | positive   | < 10   |
| 131 |         | 3.88%      | positive | 80  |         | positive   | < 10   |
| 146 |         | 8.79%      | positive | 15  |         | weak positive | < 10 |
| 149 |         | 4.31%      | positive | 20  |         | positive   | < 10   |
| 158 |         | 4.04%      | positive | 80  |         | positive   | < 10   |
| 160 |         | 3.78%      | positive | 320 |         | positive   | < 10   |
| 166 |         | 4.55%      | positive | 120 |         | positive   | < 10   |
| 187 |         | 4.63%      | positive | 180 |         | positive   | < 10   |
| 208 |         | 6.09%      | positive | 10  |         | weak positive | < 10 |
| 217 |         | 7.84%      | positive | 30  |         | positive   | < 10   |
| 228 |         | 4.44%      | positive | 120 |         | positive   | < 10   |
| 232 |         | 10.92%     | positive | 10  |         | weak positive | < 10 |
| 288 |         | 4.48%      | positive | 320 |         | positive   | < 10   |
| 289 |         | 9.16%      | positive | 60  |         | positive   | < 10   |
| 292 |         | 5.09%      | positive | 40  |         | positive   | < 10   |
| 297 |         | 5.35%      | positive | 480 |         | positive   | < 10   |
| 312 |         | 5.12%      | positive | 60  |         | positive   | < 10   |
| 313 |         | 4.92%      | positive | 160 |         | positive   | < 10   |
| 330 |         | 7.98%      | positive | 80  |         | positive   | < 10   |
| 336 |         | 4.18%      | positive | 120 |         | positive   | < 10   |
| 337 |         | 4.44%      | positive | 160 |         | positive   | < 10   |
| 343 |         | 7.08%      | positive | 10  |         | weak positive | < 10 |

ELISA positive and WNV-NT negative (n=7)

| No. | Percentage | Status |
|-----|------------|--------|
| 98  | 34.70%     | < 10   |
| 106 | 26.64%     | < 10   |
| 183 | 14.07%     | < 10   |
| Sample | Percentage | ELISA | NT | Result | ELISA | NT |
|--------|------------|-------|----|--------|-------|----|
| 230    | 23.58%     | positive | < 10 | negative | < 10 | negative |
| 250    | 30.98%     | positive | < 10 | negative | < 10 | negative |
| 295    | 25.88%     | positive | < 10 | negative | < 10 | negative |
| 328    | 39.16%     | positive | < 10 | negative | < 10 | negative |

**ELISA negative and WNV-NT positive (n=4)**

| Sample | Percentage | ELISA | NT | Result | ELISA | NT |
|--------|------------|-------|----|--------|-------|----|
| 209    | 91.31%     | negative | 30 | positive | < 10 | negative |
| 210    | 86.89%     | negative | 120 | positive | < 10 | negative |
| 212    | 90.21%     | negative | 10 | weak positive | < 10 | negative |
| 214    | 93.03%     | negative | 320 | positive | < 10 | negative |

**Low volume ➔ no ELISA, WNV-NT positive (n=3)**

| Sample | ELISA | NT | Result | ELISA | NT |
|--------|-------|----|--------|-------|----|
| 126    | n.d.  | *  | 80     | positive | < 10 | negative |
| 127    | n.d.  | *  | 60     | positive | < 10 | negative |
| 162    | n.d.  | *  | 60     | positive | < 10 | negative |

**Low volume ➔ no ELISA, WNV-NT negative (n=11+1 not evaluable)**

| Sample | ELISA | NT | Result | ELISA | NT |
|--------|-------|----|--------|-------|----|
| 27     | n.d.  | *  | < 10   | negative | < 10 | negative |
| 76     | n.d.  | *  | < 10   | negative | < 10 | negative |
| 100    | n.d.  | *  | not evaluable, because of serum toxicity for cells |
| 125    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 129    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 130    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 138    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 139    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 163    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 179    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 180    | n.d.  | *  | < 10   | negative | < 10 | negative |
| 186    | n.d.  | *  | < 10   | negative | < 10 | negative |

In summary, our results show that WNV circulates in large parts of Ukraine. In total, 42 horse sera (Table 3) tested positive for WNV antibodies as determined by both ELISA and NT. These samples were collected in seven regions, namely Kharkivska, Khmelnitska, Kyivska, Kirovohradska, Luhanska, Poltavska and Zaporizka (Figure 3, Table 4).
Figure 3. Number of WNV positive sera (red columns = both in ELISA and NT) in horses from different Ukrainian regions. ELISA negative samples are depicted in green columns.

Table 4. Distribution of the ELISA and NT positive samples.

| Ukraine | region      | comp. ELISA positive and WNV-NT positive | WNV-NT ND50 titres |
|---------|-------------|------------------------------------------|--------------------|
| 1       | Donetsk     | -                                        | -                  |
| 2       | Kharkivska  | 4                                        | 10 - 160           |
| 3       | Khmelnytska | 1                                        | 10                 |
| 4       | Kyivska     | 17                                       | 10 - 640           |
| 5       | Kirovohradsk | 11                                       | 30 - 160           |
| 6       | Luhanska    | 3                                        | 15 - 120           |
| 7       | Odeska      | -                                        | -                  |
| 8       | Poltavska   | 1                                        | 40                 |
| 9       | Rivnenska   | -                                        | -                  |
| 10      | Sumska      | -                                        | -                  |
| 11      | Vinnytska   | -                                        | -                  |
| 12      | Volynska    | -                                        | -                  |
| 13      | Zaporizka   | 5                                        | 60 - 480           |
| 14      | Zhytomyrska | -                                        | -                  |
The overall findings reported here are consistent with those from previous WNV seroprevalence studies in horses, mosquitoes and wild birds [7,19,21,29,30] and humans [19,20,29] in Ukraine. Most recently, high infection rates have also been found in humans in Romania and the Russian Federation, which are immediate neighbors of Ukraine [6,12]. Large parts of the Ukrainian landscape (rivers, wetlands and lowlands) and the country’s climatic conditions (wet winters and springs followed by excessive heat in the summers) are commensurate with environmental conditions necessary for productive circulation of WNV in wildlife. Moreover, Ukraine is located on major migratory bird flyways connecting Africa and The Middle East with Eurasia [31]. WNV endemics establish themselves particularly in urban regions with open water drainage systems and improper basic sanitation [32]. During the time of sampling, no clinical WNV cases were reported in horses, whereas clinical cases were confirmed in humans in 2011 and 2012 in Ukraine [23-25].

To exclude serological cross-reactions leading to false WNV seropositivity, differential diagnostic assays were conducted. As the WNV ELISA used also detects cross-reacting antibodies induced by other flaviviruses, e.g. TBEV [26-28], all sera negative in the WNV NT were also screened using a TBEV NT (Table 3) as well as a Japanese encephalitis virus (JEV) NT, all with negative outcomes (data not shown). The reason for ELISA reactivity of the seven sera (positive WNV ELISA, but negative in all conducted NTs, Table 3) is unclear at present. Besides measuring different properties of antibodies in the assay systems, this may indicate circulation of an as-yet-unknown flavivirus in Ukraine.

3. Experimental Materials and Methods

*Serum samples.* Blood samples were collected from 310 randomly selected healthy horses, which were kept in 14 regions of Ukraine during 2010 and 2011 (Table 1). Horses had no known clinical history of a previous WNV infection. Sera were kept at –20 °C until use.

*ELISA.* Sera were screened for WNV specific antibodies using a commercially available competition ELISA, which allows the species-independent recognition of WNV antibodies against the PrM- and E envelope protein (ID Screen® West Nile Competition, IDVet, Montpellier, France). The ELISA cut-off is defined by the residual binding ratios (S/N%-value); sera with S/N ratios of 40% and lower are positive, while samples with S/N ratios of more than 50 are considered WNV antibody-negative. S/N values of 40–50% are inconclusive. Additionally, a commercially available IgM capture ELISA was used (IDEXX IgM WNV Ab Test, IDEXX Europe B.V., Hoofddorp, the Netherlands) to detect recent WNV infection in horses.

*NT.* ELISA results were confirmed by virus neutralization test carried out under biosafety level 3 conditions and using Vero cells on 96-well plates as described earlier [33]. Test serum dilutions (20 µl starting heat-inactivated serum material) were pre-incubated with 100 TCID₅₀ of WNV strain Austria (lineage 2, Accession no. HM015884, kindly provided by Dr. N. Nowotny, Institute of Virology, University of Veterinary Medicine, Vienna). All samples were run in duplicate and NT titers were calculated after inspection of the assay at 6 to 7 days after infection, depending on the cytopathic effects in the infected control wells. The neutralizing antibody titer was defined as the neutralization dose 50% (ND₅₀), i.e. the maximum dilution, which inhibited cytopathic effects in 50% of the wells according to the Behrens-Kaerber method. ND₅₀ values of above 10 were considered positive. The
TBEV serum neutralization test was carried out following the same protocol, except that the TBEV strain Neudoerfl (kindly provided by Dr. F. Hufert, Institute for Virology, Göttingen Germany; GenBank accession no. U27495) was used. Furthermore, JEV-NT was carried out using the same procedure and using JEV strain Nakayama (GenBank accession no. EF571853).

Maps. GIS-Analysis of the sampling sites and of the results was performed by using the ArcGIS Arview 10.0 software (ESRI, Redlands, CA, USA) and displayed using a Lambert conformal conic coordinate system.

4. Conclusions

WNV specific antibodies were detected in sera from horses originating from seven Ukrainian regions, thus representing a substantial part of the country’s territory (Figure 1), and the mean sero-prevalence rate for WNV was 13.5% indicating an existing infection occasion. However, IgM ELISA analyses on selective sera did not reveal any evidence of recent infections. Samples were unsuitable for the demonstration of WNV genomes.

This is the first up-to-date report indicating WNV infections prevalence in horses in Ukraine, and these results provide evidence of widespread WNV circulation in this country. The results will help to determine the risk of infection for humans and to control WNV transmission. Surveillance studies in humans, vectors and animals are needed to better define endemic areas.

Acknowledgments

We thank Tobias Winterfeld and Cornelia Steffen for their excellent technical assistance. This study was partially funded by NADIR and by EU grant FP7-261504 EDENext and is catalogued by the EDENext Steering Committee as EDENext181 (http://www.edenext.eu). The contents of this publication are the sole responsibility of the authors and don’t necessarily reflect the views of the European Commission.

Conflict of Interest

The authors declare no conflict of interest.

References and Notes

1. Calistri, P.; Giovannini, A.; Hubalek, Z.; Ionescu, A.; Monaco, F.; Savini, G.; Lelli, R. Epidemiology of West Nile in europe and in the Mediterranean basin. Open Virol. J. 2010, 4, 29-37.
2. Weissenbock, H.; Hubalek, Z.; Bakonyi, T.; Nowotny, N. Zoonotic mosquito-borne flaviviruses: worldwide presence of agents with proven pathogenicity and potential candidates of future emerging diseases. Vet. Microbiol. 2010, 140, 271-280.
3. van der Meulen, K.M.; Pensaert, M.B.; Nauwynck, H.J. West Nile virus in the vertebrate world. Arch. Virol. 2005, 150, 637-657.
4. Turell, M.J. Members of the Culex pipiens complex as vectors of viruses. J. Am. Mosq. Control Assoc. 2012, 28, 123-126.
5. Garcia-Bocanegra, I.; Jaen-Tellez, J.A.; Napp, S.; Arenas-Montes, A.; Fernandez-Morente, M.; Fernandez-Molera, V.; Arenas, A. West Nile fever outbreak in horses and humans, Spain, 2010. *Emerg. Infect. Dis.* 2011, 17, 2397-2399.

6. Tsai, T.F.; Popovici, F.; Cernescu, C.; Campbell, G.L.; Nedelcu, N.I. West Nile encephalitis epidemic in southeastern Romania. *Lancet* 1998, 352, 767-771.

7. Hubalek, Z. Mosquito-borne viruses in Europe. *Parasitol. Res.* 2008, 103 Suppl 1, S29-43.

8. Lvov, D.K.; Butenko, A.M.; Gromashevsky, V.L.; Kevtunov, A.I.; Prilipov, A.G.; Kinney, R.; Aristova, V.A.; Dzharkenov, A.F.; Samokhvalov, E.I.; Savage, H.M., *et al.* West Nile virus and other zoonotic viruses in Russia: examples of emerging-reemerging situations. *Arch. Virol. Suppl.* 2004, 85-96.

9. Murgue, B.; Murri, S.; Zientara, S.; Durand, B.; Durand, J.P.; Zeller, H. West Nile outbreak in horses in southern France, 2000: the return after 35 years. *Emerg. Infect. Dis.* 2001, 7, 692-696.

10. Pfeffer, M.; Dobler, G. Emergence of zoonotic arboviruses by animal trade and migration. *Parasit. Vectors* 2010, 3, 35.

11. De Filette, M.; Ulbert, S.; Diamond, M.; Sanders, N.N. Recent progress in West Nile virus diagnosis and vaccination. *Vet. Res.* 2012, 43, 16.

12. Lvov, D.K.; Butenko, A.M.; Gromashevsky, V.L.; Larichev, V.P.; Gaidamovich, S.Y.; Vyshemirsky, O.I.; Zhukov, A.N.; Lazorenko, V.V.; Salko, V.N.; Kevtunov, A.I., *et al.* Isolation of two strains of West Nile virus during an outbreak in southern Russia, 1999. *Emerg. Infect. Dis.* 2000, 6, 373-376.

13. Komar, N. West Nile virus: epidemiology and ecology in North America. *Adv Virus Res* 2003, 61, 185-234.

14. Papa, A. West Nile virus infections in Greece: an update. *Expert Rev. Anti Infect. Ther.* 2012, 10, 743-750.

15. Hubalek, Z.; Ludvikova, E.; Jahn, P.; Treml, F.; Rudolf, I.; Svobodova, P.; Sikutova, S.; Betasova, L.; Bires, J.; Mojzis, M., *et al.* West Nile Virus Equine Serosurvey in the Czech and Slovak Republics. *Vector Borne Zoonotic Dis.* 2013, [Epub ahead of print].

16. Promedmail: Archive Number: 20120921.1304610 Available online: http://www.promedmail.org (accessed on 13.08.2013).

17. Monaco, F.; Savini, G.; Calisti, P.; Polci, A.; Pinoni, C.; Bruno, R.; Lelli, R. 2009 West Nile disease epidemic in Italy: first evidence of overwintering in Western Europe? *Res. Vet. Sci.* 2011, 91, 321-326.

18. Savini, G.; Puggioni, G.; Di Gennaro, A.; Di Francesco, G.; Rocchigiani, A.M.; Polci, A.; Marini, V.; Pinoni, C.; Rolesu, S.; Marruchella, G., *et al.* West Nile virus lineage 2 in Sardinian wild birds in 2012: a further threat to public health. *Epidemiol. Infect.* 2013, 1-4.

19. Sidenko, V.P.; Stepankovskaia, L.D.; Solomko, R.M.; Poliakov, E.M.; Grekov, V.S.; Mosketi, K.B.; Scharanova, O.K.; Alekseenko, O.A.; Woljanskaia, E.A.; Fiadina, D.D. [Results of a study of West Nile fever in the South of the European part of the USSR]. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 1974, 00, 129.

20. Buletsa, B.A.; Turak Iu, A.; Korol, M.; Ignatovich, II; Vitvitskii, A.A. [Neurologic manifestations of West Nile fever in the Transcarpathian region]. *Zh. Nevropatol. Psihhiatr. Im. S. S. Korsakova* 1989, 89, 29-30.
21. Vinograd, I.A.; Beletskaia, G.V.; Chumachenko, S.S.; Ardamatskaia, T.B.; Rogochii, E.G.; Lutsik, B.D.; Palchevski, N.V.; Vigovksy, A.I.; Olmelchenko, A.A. [Isolation of West Nile virus in the Southern Ukraine]. Vopr. Virusol. 1982, 27, 567-569.

22. Lozyns'kyi, I.M.; Vynohrad, I.A. [Arboviruses and arbovirus infections in the forest steppe zone of Ukraine]. Mikrobiol. Z. 1998, 60, 49-60.

23. ECDC, European Centers for Disease Prevention and Control: West Nile Fever Map - Table on cases 2011. Available online: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/2010-table.aspx (accessed on August 13 2013).

24. ECDC, E.C.f.D.P.a.C.: West Nile Fever Map - Table on cases 2012. Available online: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/2012-table.aspx (accessed on August 13 2013).

25. Giese, C.; Ait el Belghiti, F.; Barboza, P. and all National EpiSouth Focal Points: West Nile Virus Circulation in the EpiSouth countries and neighbouring areas, Seasons 2010 and 2011. Update 1st July 2012. Available online: http://www.episouthnetwork.org/sites/default/files/outputs/note_west_nile_episouth_2010_2011_july2012.pdf (accessed on August 13 2013).

26. Ziegler, U.; Seidowski, D.; Angenvoort, J.; Eiden, M.; Müller, K.; Nowotny, N.; Groschup, M.H. Monitoring of West Nile virus infections in Germany. Zoon. Public Health 2012, 59 Suppl 2, 95-101.

27. Rushton, J.O.; Lecollinet, S.; Hubalek, Z.; Svobodova, P.; Lussy, H.; Nowotny, N. Tick-borne Encephalitis Virus in Horses, Austria, 2011. Emerg. Infect. Dis. 2013, 19, 635-637.

28. Ziegler, U.; Angenvoort, J.; Klaus, C.; Nagel-Kohl, U.; Sauerwald, C.; Thalheim, S.; Horner, S.; Braun, B.; Kenkies, S.; Tyczka, J., et al. Use of competition ELISA for monitoring of west nile virus infections in horses in Germany. Int. J. Environ. Res. Public Health 2013, 10, 3112-3120.

29. Hubalek, Z.; Halouzka, J. West Nile fever - a reemerging mosquito-borne viral disease in Europe. Emerg. Infect. Dis. 1999, 5, 643-650.

30. Vinograd, I.A.; Beletskaia, G.V.; Chumachenko, S.S.; Omelchenko, G.A.; Lozinski, I.N.; Yartys, O.S., et al. [Ecological aspects of arbovirus studies in the Ukrainian SSR]. In Ecology of viruses and diagnostics of arbovirus infections., Lvov, D.K.; Gaidamovich, S.Y., Eds. Acad Med Sci USSR: Moscow, 1989; pp 21 - 27.

31. Atkinson, P.W.; Clark, J.A.; Delany, S.; Diagina, C.H.; du Feu, C.; Fiedler, W.; Fransson, T.; Gauthier-Clerc, M.; Grantham, M.; Gschweng, M., et al.: Urgent preliminary assessment of ornithological data relevant to the spread of Avian Influenza in Europe. Report to the European Commission. May 2006. Available online: http://ec.europa.eu/environment/nature/conservation/wildbirds/birdflue/index_en.htm (accessed on August 18 2013).

32. Reiter, P. West Nile virus in Europe: understanding the present to gauge the future. Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin. 2010, 15, 19508.
33. Seidowski, D.; Ziegler, U.; von Rönn, J.A.; Müller, K.; Hüppop, K.; Müller, T.; Freuling, C.; Mühle, R.U.; Nowotny, N.; Ulrich, R.G., et al. West Nile virus monitoring of migratory and resident birds in Germany. Vector Borne Zoonotic Dis. 2010, 10, 639-647.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).